Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28195741 | 0.88 | SLC22A12 (0.46) | ARTRPV4SLC22A12PGR | |
| SCHEMBL12586925 | 0.83 | AR (0.44) | ARTRPV4SLC22A12PGRMRGPRX4 | |
| SCHEMBL7059101 | 0.82 | AR (0.53) | ARTRPV4SLC22A12PGRMRGPRX4 | |
| SCHEMBL5537728 | 0.82 | GPR3 (0.41) | SLC22A12PGRMRGPRX4GPR3SCN5A | |
| SCHEMBL29172848 | 0.82 | GPR3 (0.41) | ARSLC22A12MRGPRX4GPR3SCN5A | |
| SCHEMBL28364202 | 0.80 | TRPV4 (0.48) | ARTRPV4PGRGPR3CYP11B2 | |
| SCHEMBL26127201 | 0.79 | AR (0.49) | ARTRPV4PGRMRGPRX4CYP11B2 | |
| SCHEMBL23831366 | 0.79 | SCN5A (0.41) | ARPGRGPR3TRPA1SCN5A | |
| SCHEMBL16955309 | 0.79 | GPR3 (0.41) | ARPGRGPR3TRPA1SCN5A | |
| SCHEMBL6946306 | 0.79 | AR (0.47) | ARPGRMRGPRX4GPR3TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| CN-107750250-B | Indolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| CN-107635970-B | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3288936-B1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| CN-101031557-A | Substituted quinolones | AICURIS GMBH & CO KG (DE) | 2007-09-05 | — | — | CN | disclosed |
| WO-2007090579-A2 | SUBSTITUTED QUINOLONES III | AICURIS GMBH & CO. KG (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090579-A2 | SUBSTITUTED QUINOLONES III | AICURIS GMBH & CO. KG (DE) | 2007-08-16 | — | — | WO | disclosed |
| EP-1768973-A1 | SUBSTITUTED QUINOLONES | AiCuris GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2007003308-A1 | SUBSTITUTED QUINOLONES II | AICURIS GMBH & CO. KG (DE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003308-A1 | SUBSTITUTED QUINOLONES II | AICURIS GMBH & CO. KG (DE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006008046-A1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO. KG (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | GRIN1, GABRE, GRIN3A | AR 1358/4885TRPV4 367/4885SLC22A12 1349/4885 |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | AR 4478/4885TRPV4 79/4885SLC22A12 1483/4885 |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | KCNJ11, KCNJ1, KCNJ8 | AR 4478/4885TRPV4 79/4885SLC22A12 1483/4885 |
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | AR 4880/4885TRPV4 4723/4885SLC22A12 3301/4885 |
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | AR 713/4885TRPV4 474/4885SLC22A12 1082/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | AR 4478/4885TRPV4 79/4885SLC22A12 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.